From the Guidelines
A typical trial period for Strattera (atomoxetine) is at least 6-8 weeks, considering the dose titration schedule, which usually takes 7-14 days to adjust, and allowing time to assess the full therapeutic effect at the target dose. According to the study published in the American Journal of Obstetrics and Gynecology in 2024 1, the dose of atomoxetine is usually adjusted every 7-14 days, starting from 40 mg daily, and titrated up to 60 and then 80 mg daily, with a maximum recommended dose of 1.4 mg/kg/day or 100 mg/day. During this trial period:
- Take the medication daily as prescribed
- Monitor for side effects, such as nausea, decreased appetite, and fatigue
- Keep a log of symptom improvements It is essential to note that atomoxetine does not seem to be associated with major congenital malformations or other significant adverse obstetrical or developmental outcomes, although data are limited 1. The medication works by increasing norepinephrine levels in the brain, which can improve attention and impulse control, but its effects may not be apparent until after several weeks of consistent use at the target dose. If no significant improvement is seen after the trial period, it is crucial to consult a healthcare provider about adjusting the dose or considering alternative treatments.
From the FDA Drug Label
Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials of atomoxetine hydrochloride in children and adolescents The efficacy of atomoxetine capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 to 18), two 10-week trial in adults, and one maintenance trial in pediatrics (ages 6 to 15)
The duration of an Atomoxetine (Strattera) trial is 6 to 18 weeks for short-term placebo-controlled trials, with specific trial durations ranging from 6 to 9 weeks for pediatric patients and 10 weeks for adults 2.
From the Research
Duration of Atomoxetine Trial
- The duration of an Atomoxetine (Strattera) trial is typically 10 weeks, as seen in two large, well-controlled trials in adults with ADHD 3, 4.
- These trials assessed the efficacy and tolerability of oral atomoxetine (60,90, or 120 mg/day) compared to placebo.
- A noncomparative, 34-week extension phase was also conducted to demonstrate continued efficacy 3, 4.
- It's worth noting that the provided studies do not mention the duration of Atomoxetine trials beyond the 10-week and 34-week periods mentioned above.
- Other studies, such as those on escitalopram, natalizumab, and cabotegravir, do not provide relevant information on the duration of Atomoxetine trials 5, 6, 7.